Get the Stockscreener App
19.40
0.56%
-0.11
After Hours:
19.40
Theravance Biopharma Inc stock is traded at $19.40, with a volume of 294.67K.
It is down -0.56% in the last 24 hours and down -1.27% over the past month.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$19.51
Open:
$19.69
24h Volume:
294.67K
Relative Volume:
0.62
Market Cap:
$983.05M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
-21.09
EPS:
-0.92
Net Cash Flow:
$-9.60M
1W Performance:
-0.92%
1M Performance:
-1.27%
6M Performance:
+62.75%
1Y Performance:
+107.26%
1-Day Range:
$19.09
$19.69
1-Week Range:
$18.45
$20.60
52-Week Range:
$7.90
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
19.40 | 988.62M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-12-25 | Initiated | B. Riley Securities | Buy |
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Baader Bank Aktiengesellschaft Invests $781,000 in Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Biopharma Inc (NASDAQ:TBPH) Shows Strong Technical and Fundamental Momentum - ChartMill
Is Theravance Biopharma Inc. stock showing strong momentumJuly 2025 Macro Moves & Weekly Setup with ROI Potential - mfd.ru
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Precision Trading with Theravance Biopharma Inc. (TBPH) Risk Zones - Stock Traders Daily
RSI Check: Can Theravance Biopharma Inc sustain its profitabilityEarnings Risk Summary & Weekly High Return Stock Forecasts - baoquankhu1.vn
A Glimpse Into The Expert Outlook On Theravance Biopharma Through 4 Analysts - Benzinga
Theravance Biopharma's (TBPH) "Buy" Rating Reaffirmed at BTIG Research - MarketBeat
TBPH Stock: BTIG Reiterates 'Buy' Rating at $40 Target Price | T - GuruFocus
While shareholders of Theravance Biopharma (NASDAQ:TBPH) are in the black over 1 year, those who bought a week ago aren't so fortunate - simplywall.st
Is the Options Market Predicting a Spike in Theravance Biopharma Stock? - sharewise.com
Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Above Fifty Day Moving AverageHere's What Happened - MarketBeat
Technical Reactions to TBPH Trends in Macro Strategies - Stock Traders Daily
Theravance Biopharma stock hits 52-week high at $21.01 By Investing.com - au.investing.com
Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Profit Review: Is Theravance Biopharma Inc affected by consumer sentimentSell Signal & Safe Entry Zone Identification - baoquankhu1.vn
Theravance Biopharma stock hits 52-week high at $21.01 - Investing.com
Theravance Biopharma (NASDAQ:TBPH) Reaches New 1-Year HighHere's What Happened - MarketBeat
Neurogenic Orthostatic Hypotension (nOH) Global Clinical Trials Market Review 2025: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status - GlobeNewswire Inc.
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term - sharewise.com
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Theravance Biopharma stock hits 52-week high at 20.69 USD By Investing.com - Investing.com Nigeria
Theravance Biopharma stock hits 52-week high at 20.69 USD - Investing.com
Trading the Move, Not the Narrative: (TBPH) Edition - Stock Traders Daily
Theravance Biopharma (NASDAQ:TBPH) Sets New 12-Month HighWhat's Next? - MarketBeat
Theravance Biopharma CEO earns 2026 Honorable Mentor title - Traders Union
Theravance Biopharma, Inc. Announces Upcoming Phase 3 Data for Ampreloxetine - TradingView — Track All Markets
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Unpacking A 40% Potential Upside - DirectorsTalk Interviews
What valuation ratios show for Theravance Biopharma Inc. (0TB) stockJuly 2025 Technicals & Reliable Entry Point Alerts - Улправда
Chart Watch: What valuation ratios show for Theravance Biopharma Inc. (0TB) stockWeekly Trend Recap & Smart Investment Allocation Tips - Улправда
Will Theravance Biopharma Inc. stock deliver better than expected guidanceMarket Activity Summary & Verified Momentum Stock Ideas - Улправда
Published on: 2026-01-08 18:37:29 - Улправда
mF International, Theravance Biopharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Theravance Biopharma (NASDAQ:TBPH) Share Price Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Share Price Crosses Above Fifty Day Moving Average – What’s Next? - Defense World
(TBPH) Volatility Zones as Tactical Triggers - Stock Traders Daily
Theravance Biopharma (NASDAQ:TBPH) Lowered to Buy Rating by Wall Street Zen - MarketBeat
Portfolio Update: Why Theravance Biopharma Inc 0TB stock stays resilient2025 Short Interest & Daily Entry Point Alerts - moha.gov.vn
Can Theravance Biopharma's Ampreloxetine Fill The Gap In MSA-Related NOH Therapy? - RTTNews
Market Overview: Is Theravance Biopharma Inc stock trading near support levels2025 Macro Impact & Weekly Return Optimization Plans - Bộ Nội Vụ
What drives Theravance Biopharma Inc stock priceMarket Insider Reports & Build Your Portfolio With Our Free Stock Scanner - earlytimes.in
Inspire Investing LLC Purchases New Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
Here's Why Theravance Biopharma (TBPH) is a Strong Growth Stock - sharewise.com
(TBPH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here's is How to Trade - Finviz
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):